Table 1.
Drugs for the treatment of osteoporosis.
| Drug Names | Description | Indication | |
|---|---|---|---|
| Anti-Resorptive | |||
| Selective oestrogen-receptor modulators | Raloxifene | They act as estrogen receptor agonists, thereby decreasing bone resorption. | - Postmenopausal OP - Postmenopausal OP with a high fracture risk |
| Bazedoxifene | |||
| Calcitonin | Their main function is to prevent the loss of bone mass due to sudden immobilization. | - Immobilizations | |
| Bisphosphonates | Alendronate | They are the first choice in postmenopausal osteoporosis. They act by binding to the bone and preventing bone resorption. | - Postmenopausal OP - Postmenopausal OP with a high fracture risk - Advanced neoplasia with bone involvement and tumor-induced hypercalcemia |
| Risedronate | |||
| Ibandronate | |||
| Zoledronic acid | |||
| RANKL antibody | Denosumab | Human IgG2 monoclonal antibody that has a high specificity and affinity for RANKL, which it binds and inhibits. | - Advanced neoplasia with bone involvement - Treatment of giant cell tumors of unresectable bone or when surgical resection involves severe morbidity |
| Anabolic Agents | |||
| Parathyroid hormone analogs | Teriparatide | Increases bone formation with minor increases in bone resorption, resulting in a net anabolic effect. | - Postmenopausal OP and men at a high fracture risk - OP associated with glucocorticoid treatment in women and men at a high fracture risk |
| Abaloparatide | |||
OP: Osteoporosis.